Drug intelligence / Profile preview

CB008

Development stage: Preclinical
Lead developer: Siemens

Overview

**CB008** is a prescription drug developed by Canopus BioPharma Inc., initially by Canopus Holding SA, with demonstrated in vitro efficacy against Ebola virus and signed agreements for further development with major pharmaceutical companies. It targets infectious diseases, showing positive results in live Ebola virus studies as a safe and effective treatment. Current global R&D status is pending, with limited public details on its mechanism, clinical progression, or specific indications beyond infectious diseases like Ebola.[1][3][7]

Beyond the preview

Go deeper on CB008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB008.

Explore the full profile